• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.

作者信息

Harries A D, Lin Y, Thekkur P, Nair D, Chakaya J, Dongo J P, Luzze H, Chimzizi R, Mubanga A, Timire C, Kavenga F, Satyanarayana S, Kumar A M V, Khogali M, Zachariah R

机构信息

International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.

International Union Against Tuberculosis and Lung Disease, Paris, France.

出版信息

Int J Tuberc Lung Dis. 2023 Jul 1;27(7):495-498. doi: 10.5588/ijtld.23.0178.

DOI:10.5588/ijtld.23.0178
PMID:37353872
Abstract
摘要

相似文献

1
Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.为何结核病防治项目应在结核病治疗开始时和结束时评估合并症、决定因素及残疾情况。
Int J Tuberc Lung Dis. 2023 Jul 1;27(7):495-498. doi: 10.5588/ijtld.23.0178.
2
A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center.耐多药结核病病例临床特征研究及耐药结核病中心收治的耐多药结核病病例开始二线抗结核治疗所面临挑战的评估。
Indian J Tuberc. 2019 Jul;66(3):358-363. doi: 10.1016/j.ijtb.2016.11.031. Epub 2017 Feb 10.
3
Proportions and determinants of successful tuberculosis treatment among tuberculosis patients with comorbidity registered in National Tuberculosis Registry in Negeri Sembilan from year 2018-2023.2018年至2023年在森美兰州国家结核病登记处登记的合并症结核病患者中成功治疗结核病的比例及决定因素。
Med J Malaysia. 2025 Jan;80(1):50-59.
4
Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007-2014: a national cohort study.芬兰 2007-2014 年影响肺结核治疗结果的危险因素：一项全国队列研究。
BMC Public Health. 2020 Aug 17;20(1):1250. doi: 10.1186/s12889-020-09360-7.
5
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.利福平耐药或利福平不良反应肺结核患者利福平节约治疗的治疗结局：回顾性队列分析。
Respir Med. 2017 Oct;131:43-48. doi: 10.1016/j.rmed.2017.08.002. Epub 2017 Aug 4.
6
Understanding how geographic, demographic and treatment history impact health outcomes of patients with multi-drug-resistant tuberculosis in Pakistan, 2014-2017.了解 2014-2017 年巴基斯坦耐多药结核病患者的地理、人口和治疗史如何影响其健康结果。
Epidemiol Infect. 2020 Sep 30;148:e253. doi: 10.1017/S0950268820002307.
7
Smoking increases risk of recurrence after successful anti-tuberculosis treatment: a population-based study.吸烟会增加抗结核治疗成功后复发的风险：一项基于人群的研究。
Int J Tuberc Lung Dis. 2014 Apr;18(4):492-8. doi: 10.5588/ijtld.13.0694.
8
Outcomes in HIV-infected patients who develop tuberculosis after starting antiretroviral treatment in Malawi.马拉维开始抗逆转录病毒治疗后发生结核病的艾滋病毒感染患者的治疗结果。
Int J Tuberc Lung Dis. 2008 Jun;12(6):692-4.
9
Risk factors for drug-resistant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China, during 2004-2019.耐药结核病的危险因素、合并症状况与耐药模式之间的关系：中国山东 2004-2019 年既往治疗肺结核的回顾性研究。
BMJ Open. 2021 Jun 16;11(6):e044349. doi: 10.1136/bmjopen-2020-044349.
10
Clinical, Radiological Features and Treatment Outcomes of Tuberculosis in Patients Aged 75 Years and Older.75岁及以上患者结核病的临床、放射学特征及治疗结果
J Epidemiol Glob Health. 2024 Dec;14(4):1591-1601. doi: 10.1007/s44197-024-00311-8. Epub 2024 Oct 29.

引用本文的文献

1
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe.肯尼亚、乌干达、赞比亚和津巴布韦治疗开始时的结核病残疾和多种疾病并存情况。
IJTLD Open. 2025 May 12;2(5):291-298. doi: 10.5588/ijtldopen.25.0171. eCollection 2025 May.
2
Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.结核病治疗后残疾、合并症及危险因素评估：18至24个月随访
IJTLD Open. 2025 May 12;2(5):299-305. doi: 10.5588/ijtldopen.25.0149. eCollection 2025 May.
3
Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe.
肯尼亚、乌干达、赞比亚和津巴布韦结核病治疗结束时的残疾、合并症及风险决定因素。
IJTLD Open. 2024 May 1;1(5):197-205. doi: 10.5588/ijtldopen.24.0082. eCollection 2024 May.
4
Assessing for comorbidities, determinants and disability during TB treatment.在结核病治疗期间评估合并症、决定因素和残疾情况。
IJTLD Open. 2024 Feb 1;1(2):99-100. doi: 10.5588/ijtldopen.23.0441. eCollection 2024 Feb.
5
The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study.波兰合并症对结核病治疗结局的影响：一项全国队列研究。
Front Public Health. 2023 Sep 5;11:1253615. doi: 10.3389/fpubh.2023.1253615. eCollection 2023.